Several biopharma and med-tech firms announced significant leadership appointments, restructurings, and workforce adjustments. Korro Bio, despite cutting 20% of staff, reaffirmed its clinical development strategy under new CSO Loïc Vincent, focusing on RNA-edited therapies. GSK is laying off 150 employees while transferring vaccine manufacturing to expanded Pennsylvania facilities. Genentech implemented 87 job cuts amid operational realignment. Leadership roles shifted in companies like Inmagene-Ikena merger and U.K.'s Office of Life Sciences. These moves reflect ongoing sector adaptations in response to market conditions and strategic priorities.